120 related articles for article (PubMed ID: 3654151)
1. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.
Skórski T; Kawalec M
Invest New Drugs; 1987; 5(2):167-9. PubMed ID: 3654151
[TBL] [Abstract][Full Text] [Related]
2. Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654).
Skórski T; Kawalec M
Bone Marrow Transplant; 1987 Dec; 2(4):435-40. PubMed ID: 3332191
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic and nondividing mafosfamide-treated L 1210 cells--comparison of lines resistant and nonresistant to cyclophosphamide.
Kawalec M; Hoser G; Skórski T; Kawiak J
Folia Histochem Cytobiol; 1993; 31(2):63-6. PubMed ID: 8405569
[TBL] [Abstract][Full Text] [Related]
4. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
Kawalec M; Skórski T; Kawiak J
Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
[TBL] [Abstract][Full Text] [Related]
5. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide.
Skórski T; Kawalec M
Exp Hematol; 1988 Oct; 16(9):782-4. PubMed ID: 3049130
[TBL] [Abstract][Full Text] [Related]
6. Induction of immune resistance against L1210 lymphatic leukemia in mice after lethal irradiation and reconstruction with fetal liver cells.
Skórski T; Ratajczak MZ; Kawalec M; Kawiak J
Folia Histochem Cytobiol; 1991; 29(3):121-4. PubMed ID: 1794437
[TBL] [Abstract][Full Text] [Related]
7. Early induction of immune resistance against leukemia in mice after lethal irradiation followed by syngeneic bone marrow transplantation and injection of syngeneic leukocytes.
Skórski T; Kawalec M; Kawiak J
Transplantation; 1991 Apr; 51(4):843-7. PubMed ID: 2014540
[TBL] [Abstract][Full Text] [Related]
8. Early induction of immune resistance against leukemia in lethally total body irradiated mice reconstituted with syngeneic bone marrow cells obtained from previously immunized donor mice.
Skorski T; Kawalec M; Kawiak J
Bone Marrow Transplant; 1990 Jan; 5(1):23-7. PubMed ID: 2297588
[TBL] [Abstract][Full Text] [Related]
9. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide.
Davidoff AN; Mendelow BV
Exp Hematol; 1993 Jul; 21(7):922-7. PubMed ID: 8319782
[TBL] [Abstract][Full Text] [Related]
10. N3-methyl-mafosfamide as a chemically stable, alternative prodrug of mafosfamide.
Moon KY; Kwon CH
Bioorg Med Chem Lett; 1998 Jul; 8(13):1673-8. PubMed ID: 9873412
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
Tamayo E; Hervé P
Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
Kataoka T; Kobayashi H; Sakurai Y
Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
[No Abstract] [Full Text] [Related]
13. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.
Reissmann T; Voegeli R; Pohl J; Hilgard P
Cancer Immunol Immunother; 1989; 28(3):179-84. PubMed ID: 2924329
[TBL] [Abstract][Full Text] [Related]
14. Macromolecular DNA-damage in murine and human leukemic and lymphoid cells after in vitro exposure to ASTA Z 7557 (INN mafosfamide).
Osieka R; Pannenbäcker R; Schmidt CG
Invest New Drugs; 1984; 2(2):161-8. PubMed ID: 6469510
[TBL] [Abstract][Full Text] [Related]
15. Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557).
Kohn FR; Landkamer GJ; Sladek NE
Immunopharmacol Immunotoxicol; 1987; 9(2-3):163-76. PubMed ID: 3437102
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
17. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
Kohn FR; Sladek NE
Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
Maki PA; Sladek NE
Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
[TBL] [Abstract][Full Text] [Related]
19. Oxazaphosphorine effects in L 5222 rat leukemia.
Pohl J; Reissmann T; Voegeli R
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of immunological response induced in CD2F1 mice by administration of semisyngeneic L 1210 leukemia cells treated with cyclophosphamide.
Skórski T; Kawalec M; Kawiak J
Immunol Invest; 1987 Mar; 16(1):33-43. PubMed ID: 2956188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
